These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 38031799)

  • 1. Pirtobrutinib
    Al-Sawaf O; Jen MH; Hess LM; Zhang J; Goebel B; Pagel JM; Abhyankar S; Davids MS; Eyre TA
    Haematologica; 2024 Jun; 109(6):1866-1873. PubMed ID: 38031799
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fixed-duration pirtobrutinib plus venetoclax with or without rituximab in relapsed/refractory CLL: the phase 1b BRUIN trial.
    Roeker LE; Woyach JA; Cheah CY; Coombs CC; Shah NN; Wierda WG; Patel MR; Lamanna N; Tsai DE; Nair B; Wang C; Zhao X; Liu D; Radtke D; Chapman S; Marella N; McNeely SC; Brown JR
    Blood; 2024 Sep; 144(13):1374-1386. PubMed ID: 38861666
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Matching-Adjusted Indirect Comparison of Brexucabtagene Autoleucel (ZUMA-2) and Pirtobrutinib (BRUIN) in Patients with Relapsed/Refractory Mantle Cell Lymphoma Previously Treated with a Covalent Bruton Tyrosine Kinase Inhibitor.
    Salles G; Chen JMH; Zhang I; Kerbauy F; Wu JJ; Wade SW; Nunes A; Feng C; Kloos I; Peng W; Snider JT; Maciel D; Chan K; Keeping S; Shah B
    Adv Ther; 2024 May; 41(5):1938-1952. PubMed ID: 38494543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia.
    Mato AR; Woyach JA; Brown JR; Ghia P; Patel K; Eyre TA; Munir T; Lech-Maranda E; Lamanna N; Tam CS; Shah NN; Coombs CC; Ujjani CS; Fakhri B; Cheah CY; Patel MR; Alencar AJ; Cohen JB; Gerson JN; Flinn IW; Ma S; Jagadeesh D; Rhodes JM; Hernandez-Ilizaliturri F; Zinzani PL; Seymour JF; Balbas M; Nair B; Abada P; Wang C; Ruppert AS; Wang D; Tsai DE; Wierda WG; Jurczak W
    N Engl J Med; 2023 Jul; 389(1):33-44. PubMed ID: 37407001
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BTK inhibitor therapy is effective in patients with CLL resistant to venetoclax.
    Lin VS; Lew TE; Handunnetti SM; Blombery P; Nguyen T; Westerman DA; Kuss BJ; Tam CS; Roberts AW; Seymour JF; Anderson MA
    Blood; 2020 Jun; 135(25):2266-2270. PubMed ID: 32244251
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial.
    Jones JA; Mato AR; Wierda WG; Davids MS; Choi M; Cheson BD; Furman RR; Lamanna N; Barr PM; Zhou L; Chyla B; Salem AH; Verdugo M; Humerickhouse RA; Potluri J; Coutre S; Woyach J; Byrd JC
    Lancet Oncol; 2018 Jan; 19(1):65-75. PubMed ID: 29246803
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in patients with B-cell malignancies: analysis of the Richter transformation subgroup from the multicentre, open-label, phase 1/2 BRUIN study.
    Wierda WG; Shah NN; Cheah CY; Lewis D; Hoffmann MS; Coombs CC; Lamanna N; Ma S; Jagadeesh D; Munir T; Wang Y; Eyre TA; Rhodes JM; McKinney M; Lech-Maranda E; Tam CS; Jurczak W; Izutsu K; Alencar AJ; Patel MR; Seymour JF; Woyach JA; Thompson PA; Abada PB; Ho C; McNeely SC; Marella N; Nguyen B; Wang C; Ruppert AS; Nair B; Liu H; Tsai DE; Roeker LE; Ghia P
    Lancet Haematol; 2024 Sep; 11(9):e682-e692. PubMed ID: 39033770
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study.
    Mato AR; Shah NN; Jurczak W; Cheah CY; Pagel JM; Woyach JA; Fakhri B; Eyre TA; Lamanna N; Patel MR; Alencar A; Lech-Maranda E; Wierda WG; Coombs CC; Gerson JN; Ghia P; Le Gouill S; Lewis DJ; Sundaram S; Cohen JB; Flinn IW; Tam CS; Barve MA; Kuss B; Taylor J; Abdel-Wahab O; Schuster SJ; Palomba ML; Lewis KL; Roeker LE; Davids MS; Tan XN; Fenske TS; Wallin J; Tsai DE; Ku NC; Zhu E; Chen J; Yin M; Nair B; Ebata K; Marella N; Brown JR; Wang M
    Lancet; 2021 Mar; 397(10277):892-901. PubMed ID: 33676628
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-World Health Care Resource Use and Costs Among Patients With Chronic Lymphocytic Leukemia Treated With Venetoclax-Based and Bruton Tyrosine Kinase Inhibitor-Based Regimens in the Second-Line Setting.
    Fakhri B; Emechebe N; Manzoor BS; Jawaid D; Alhasani H; Edwards M; Tuncer HH
    JCO Oncol Pract; 2024 Aug; 20(8):1132-1139. PubMed ID: 38626366
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transcriptomic and proteomic differences in BTK-WT and BTK-mutated CLL and their changes during therapy with pirtobrutinib.
    Aslan B; Manyam G; Iles LR; Tantawy SI; Desikan SP; Wierda WG; Gandhi V
    Blood Adv; 2024 Sep; 8(17):4487-4501. PubMed ID: 38968154
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pirtobrutinib in Covalent Bruton Tyrosine Kinase Inhibitor Pretreated Mantle-Cell Lymphoma.
    Wang ML; Jurczak W; Zinzani PL; Eyre TA; Cheah CY; Ujjani CS; Koh Y; Izutsu K; Gerson JN; Flinn I; Tessoulin B; Alencar AJ; Ma S; Lewis D; Lech-Maranda E; Rhodes J; Patel K; Maddocks K; Lamanna N; Wang Y; Tam CS; Munir T; Nagai H; Hernandez-Ilizaliturri F; Kumar A; Fenske TS; Seymour JF; Zelenetz AD; Nair B; Tsai DE; Balbas M; Walgren RA; Abada P; Wang C; Zhao J; Mato AR; Shah NN
    J Clin Oncol; 2023 Aug; 41(24):3988-3997. PubMed ID: 37192437
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-world comparative effectiveness of venetoclax-obinutuzumab versus Bruton tyrosine kinase inhibitors for frontline chronic lymphocytic leukaemia.
    Ghosh N; Manzoor BS; Fakhri B; Emechebe N; Alhasani H; Skarbnik A; Jawaid D; Shadman M
    Br J Haematol; 2024 Oct; 205(4):1395-1403. PubMed ID: 39049159
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pirtobrutinib: A New and Distinctive Treatment Option for B-Cell Malignancies.
    Schultze MD; Reeves DJ
    Ann Pharmacother; 2024 Oct; 58(10):1064-1073. PubMed ID: 38235739
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BCL-2 Inhibition as Treatment for Chronic Lymphocytic Leukemia.
    Perini GF; Feres CCP; Teixeira LLC; Hamerschlak N
    Curr Treat Options Oncol; 2021 Jun; 22(8):66. PubMed ID: 34110507
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase 1b study of obinutuzumab, ibrutinib, and venetoclax in relapsed and refractory chronic lymphocytic leukemia.
    Rogers KA; Huang Y; Ruppert AS; Awan FT; Heerema NA; Hoffman C; Lozanski G; Maddocks KJ; Moran ME; Reid MA; Lucas M; Woyach JA; Whitlow WT; Jones JA; Byrd JC
    Blood; 2018 Oct; 132(15):1568-1572. PubMed ID: 30111609
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of new-generation Bruton tyrosine kinase inhibitors in chronic lymphocytic leukemia/small lymphocytic lymphoma: a systematic review and meta-analysis.
    Yin S; Zheng X; Zhang W; Zhao H; Zhang R; Li W; Chen F
    Ann Hematol; 2024 Jul; 103(7):2231-2244. PubMed ID: 37843620
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bruton's tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia.
    Deng J; Isik E; Fernandes SM; Brown JR; Letai A; Davids MS
    Leukemia; 2017 Oct; 31(10):2075-2084. PubMed ID: 28111464
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Effectiveness Outcomes of Treatments for Double-Exposed Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Patients: A Systematic Literature Review.
    Zuber M; Akkala S; Li N; Veettil SK; Tan CJ; Villa Zapata L
    Cancer Med; 2024 Sep; 13(18):e70258. PubMed ID: 39344587
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-Covalent Bruton's Tyrosine Kinase Inhibitors in the Treatment of Chronic Lymphocytic Leukemia.
    Montoya S; Thompson MC
    Cancers (Basel); 2023 Jul; 15(14):. PubMed ID: 37509309
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients.
    Mato AR; Hill BT; Lamanna N; Barr PM; Ujjani CS; Brander DM; Howlett C; Skarbnik AP; Cheson BD; Zent CS; Pu JJ; Kiselev P; Foon K; Lenhart J; Henick Bachow S; Winter AM; Cruz AL; Claxton DF; Goy A; Daniel C; Isaac K; Kennard KH; Timlin C; Fanning M; Gashonia L; Yacur M; Svoboda J; Schuster SJ; Nabhan C
    Ann Oncol; 2017 May; 28(5):1050-1056. PubMed ID: 28453705
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.